Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV

Vincenzi, Bruno; Frezza, Anna Maria; Schiavon, Gaia; Spoto, Chiara; Silvestris, Nicola; Addeo, Raffaele; Catalano, Vincenzo; Graziano, Francesco; Santini, Daniele; Tonini, Giuseppe

doi:10.1007/s00520-012-1667-5

Cited by 62 publications

(73 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relationship with age is consistent with several previous reports of taxane-induced neuropathy, including ECOG 5103 (4, 8, 36). In contrast, a number of studies of oxaliplatin-treated patients did not find an association with age (6, 7). …”

Section: Discussionmentioning

confidence: 78%

“…Unlike taxane-related CIPN, which can be reversible (2), cisplatin-induced peripheral neuropathy (CisIPN) can be cumulative and progressive and cause long-term effects on overall quality of life (QoL) and physical function (3). Studies have suggested that age, race, diabetes and obesity may be risk factors for CIPN (4, 5), but results have been conflicting (6–11). …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

Dolan

Charif

Wheeler

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose Our purpose was to characterize the clinical influences, genetic risk factors, and gene mechanisms contributing to persistent cisplatin-induced peripheral neuropathy (CisIPN) in testicular cancer survivors (TCS). Experimental Design TCS given cisplatin-based therapy completed the validated EORTC QLQ-CIPN20 questionnaire. An ordinal CisIPN phenotype was derived and associations with age, smoking, excess drinking, hypertension, body mass index, diabetes, hypercholesterolemia, cumulative cisplatin dose, and self-reported health were examined for 680 TCS. Genotyping was performed on the Illumina HumanOmniExpressExome chip. Following quality control and imputation, 5.1 million SNPs in 680 genetically European TCS formed the input set. GWAS and PrediXcan were used to identify genetic variation and genetically-determined gene expression traits, respectively, contributing to CisIPN. We evaluated two independent datasets for replication: Vanderbilt’s electronic health database, BioVU and CALGB 90401 trial. Results Eight sensory items formed a subscale with good internal consistency (Cronbach α=0.88). Variables significantly associated with CisIPN included age at diagnosis (OR per year=1.06, p=2 × 10−9), smoking (OR=1.54, p=0.004), excess drinking (OR=1.83, p=0.007), and hypertension (OR=1.61, p=0.03). CisIPN was correlated with lower self-reported health (OR=0.56; p=2.6 × 10−9) and weight gain adjusted for years since treatment (OR per Δkg/m2=1.05, p=0.004). PrediXcan identified lower expressions of MIDN and RPRD1B, and higher THEM5 expression as associated with CisIPN (p-value for each < 5 × 10−6) with replication of RPRD1B meeting significance criteria (Fisher’s combined p=0.0089). Conclusions CisIPN is associated with age, modifiable risk factors and genetically-determined expression level of RPRD1B. Further study of implicated genes could elucidate the pathophysiologic underpinnings of CisIPN.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Introductionmentioning

confidence: 99%

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

Dolan

Charif

Wheeler

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Although these associations seem plausible, because such conditions can cause a neuropathy similar to CIPN, their role as risk factors for CIPN is not yet demonstrated since most previous investigations excluded these patients and the few existing studies have conflicting results [15][16][17][18] and, to our knowledge, the available results do not refer specifically to breast cancer patients.…”

Section: Introductionmentioning

confidence: 82%

Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study

Pereira

Fontes

Sonin

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Prädiktive Faktoren für das Auftreten einer oxaliplatinbedingten chronischen Polyneuropathie sind u. a. die kumulative Oxaliplatindosis (mit deutlich steigendem Risiko bei einer Gesamtdosis ≥ 800 mg Oxaliplatin/m 2 Körperoberflä-che), eine vorausgehende akute Neurotoxizität durch die Substanz, Anämie, Hypomagnesiämie, Hypalbuminämie sowie eine Körperoberflache von über 2 m 2 [5][6][7]. Beim KRK im UICC-Stadium III trat abhängig von der Dauer der adjuvanten Therapie mit Oxaliplatin und Fluoropyrimidinen eine chronische Polyneuropathie Grad II bei 2,3 % der Patienten, bei 3-und bei 3,9 % der Patienten bei 6-monatiger adjuvanter Therapie auf.…”

Section: Polyneuropathieunclassified

Medikamentöse Behandlung gastrointestinaler Tumoren

Güthle

Seufferlein

2016

Gastroenterologe

View full text Add to dashboard Cite

Durch bessere Früherkennung, multimodale Behandlungsansätze und zahlreiche neue effektivere medikamentöse Therapieoptionen können zunehmend höhere Heilungsraten oder längere Überlebenszeiten bei gastrointestinalen Karzinomen verzeichnet werden. Dies korreliert teilweise aber mit einer längeren Exposition gegenüber Therapeutika, die Nebenwirkungen verursachen können. Viele Patienten leiden daher an therapiebedingten Spätfolgen, die ihre Lebensqualität beeinflussen. Hier wird auf die Langzeitnebenwirkungen nach kurativ intendierter medikamentöser Therapie von gastrointestinalen Karzinomen fokussiert.

show abstract

Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV

Abstract: Age, anaemia, hypoalbuminaemia, hypomagnesaemia and alcohol consumption are reliable and easily assessable clinical factors predicting incidence and length of oxaliplatin-induced neuropathy.

Cited by 62 publications

References 12 publications

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study

Medikamentöse Behandlung gastrointestinaler Tumoren

Contact Info

Product

Resources

About